PL3511333T3 - Postać krystaliczna i forma soli związku 7h-pirolo[2,3-d]pirymidyny oraz sposób ich wytwarzania - Google Patents
Postać krystaliczna i forma soli związku 7h-pirolo[2,3-d]pirymidyny oraz sposób ich wytwarzaniaInfo
- Publication number
- PL3511333T3 PL3511333T3 PL17873546T PL17873546T PL3511333T3 PL 3511333 T3 PL3511333 T3 PL 3511333T3 PL 17873546 T PL17873546 T PL 17873546T PL 17873546 T PL17873546 T PL 17873546T PL 3511333 T3 PL3511333 T3 PL 3511333T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- preparation
- method therefor
- pyrimidine compound
- salt form
- Prior art date
Links
- -1 7h-pyrrolo[2,3-d]pyrimidine compound Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611046683 | 2016-11-23 | ||
| PCT/CN2017/112493 WO2018095345A1 (zh) | 2016-11-23 | 2017-11-23 | 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 |
| EP17873546.0A EP3511333B1 (en) | 2016-11-23 | 2017-11-23 | Crystal form and salt form of 7h-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3511333T3 true PL3511333T3 (pl) | 2021-12-06 |
Family
ID=62195741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17873546T PL3511333T3 (pl) | 2016-11-23 | 2017-11-23 | Postać krystaliczna i forma soli związku 7h-pirolo[2,3-d]pirymidyny oraz sposób ich wytwarzania |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10774094B2 (pl) |
| EP (1) | EP3511333B1 (pl) |
| JP (1) | JP6788114B2 (pl) |
| KR (1) | KR102136958B1 (pl) |
| CN (1) | CN109563097B (pl) |
| AU (1) | AU2017366375B2 (pl) |
| CA (1) | CA3033456C (pl) |
| DK (1) | DK3511333T3 (pl) |
| EA (1) | EA039655B1 (pl) |
| ES (1) | ES2882214T3 (pl) |
| HU (1) | HUE055530T2 (pl) |
| MX (1) | MX381037B (pl) |
| PL (1) | PL3511333T3 (pl) |
| PT (1) | PT3511333T (pl) |
| UA (1) | UA123709C2 (pl) |
| WO (1) | WO2018095345A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111039963B (zh) * | 2019-12-31 | 2021-03-19 | 卓和药业集团有限公司 | Wxfl10203614水溶性类似物及其合成方法 |
| JP7590550B2 (ja) * | 2020-09-29 | 2024-11-26 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | ピラゾロピリジン系化合物の結晶及びその調製方法 |
| CN113372366B (zh) * | 2020-12-04 | 2022-08-30 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的盐、其晶型及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| HRP20020509B1 (en) | 1999-12-10 | 2005-06-30 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| GT200200234A (es) * | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| CN104610264A (zh) * | 2011-04-08 | 2015-05-13 | 辉瑞大药厂 | 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物 |
| PT3077395T (pt) | 2013-12-05 | 2018-01-03 | Pfizer | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas |
| GB201410816D0 (en) * | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| CN104144337B (zh) * | 2014-08-05 | 2016-07-06 | 深圳市华星光电技术有限公司 | 一种多视点立体显示器的图像显示方法及装置 |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| KR102081272B1 (ko) * | 2015-05-29 | 2020-02-25 | 우시 포춘 파마슈티컬 컴퍼니 리미티드 | Janus 키나아제 억제제 |
-
2017
- 2017-11-23 PL PL17873546T patent/PL3511333T3/pl unknown
- 2017-11-23 HU HUE17873546A patent/HUE055530T2/hu unknown
- 2017-11-23 DK DK17873546.0T patent/DK3511333T3/da active
- 2017-11-23 JP JP2019527838A patent/JP6788114B2/ja active Active
- 2017-11-23 AU AU2017366375A patent/AU2017366375B2/en active Active
- 2017-11-23 ES ES17873546T patent/ES2882214T3/es active Active
- 2017-11-23 PT PT178735460T patent/PT3511333T/pt unknown
- 2017-11-23 CN CN201780045482.4A patent/CN109563097B/zh active Active
- 2017-11-23 CA CA3033456A patent/CA3033456C/en active Active
- 2017-11-23 MX MX2019002077A patent/MX381037B/es unknown
- 2017-11-23 WO PCT/CN2017/112493 patent/WO2018095345A1/zh not_active Ceased
- 2017-11-23 UA UAA201901913A patent/UA123709C2/uk unknown
- 2017-11-23 KR KR1020197006159A patent/KR102136958B1/ko active Active
- 2017-11-23 EA EA201990364A patent/EA039655B1/ru unknown
- 2017-11-23 US US16/336,361 patent/US10774094B2/en active Active
- 2017-11-23 EP EP17873546.0A patent/EP3511333B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6788114B2 (ja) | 2020-11-18 |
| DK3511333T3 (da) | 2021-08-02 |
| CN109563097B (zh) | 2021-05-14 |
| AU2017366375B2 (en) | 2020-12-03 |
| EP3511333A4 (en) | 2019-08-28 |
| JP2019535771A (ja) | 2019-12-12 |
| CA3033456A1 (en) | 2018-05-31 |
| UA123709C2 (uk) | 2021-05-19 |
| KR20190037291A (ko) | 2019-04-05 |
| EP3511333A1 (en) | 2019-07-17 |
| EA201990364A1 (ru) | 2019-10-31 |
| US20190218231A1 (en) | 2019-07-18 |
| EA039655B1 (ru) | 2022-02-22 |
| MX381037B (es) | 2025-03-12 |
| CA3033456C (en) | 2021-03-09 |
| PT3511333T (pt) | 2021-08-02 |
| ES2882214T3 (es) | 2021-12-01 |
| CN109563097A (zh) | 2019-04-02 |
| MX2019002077A (es) | 2019-05-15 |
| US10774094B2 (en) | 2020-09-15 |
| EP3511333B1 (en) | 2021-05-12 |
| AU2017366375A1 (en) | 2019-04-18 |
| WO2018095345A1 (zh) | 2018-05-31 |
| HUE055530T2 (hu) | 2021-12-28 |
| KR102136958B1 (ko) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
| PL3429591T3 (pl) | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania | |
| SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
| EP3231805A4 (en) | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt | |
| IL258231A (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
| EP3287444A4 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| GB201502260D0 (en) | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound | |
| EP3321271A4 (en) | PROCESS FOR THE PRODUCTION OF THE 7H-PYROLLO [2,3-D] PYRIMIDINE DERIVATIVE AND THE CORRESPONDING INTERMEDIATE | |
| EP3190112A4 (en) | Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof | |
| EP3383844B8 (en) | Process for the preparation of carboprost and its tromethamine salt | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| IL276160A (en) | A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals | |
| IL260999B (en) | A method for the preparation of a pyrrolo[3,2-d] pyrimidine compound, and its intermediates | |
| PT3766884T (pt) | Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado | |
| SI2882753T1 (sl) | Postopek za pripravo pemetrekseda in njegove lizinske soli | |
| PL3511333T3 (pl) | Postać krystaliczna i forma soli związku 7h-pirolo[2,3-d]pirymidyny oraz sposób ich wytwarzania | |
| EP3369733A4 (en) | Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof | |
| EP3541391A4 (en) | ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF PREPARING AND USING THE SAME | |
| EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
| EP3719015A4 (en) | SUBSTITUTED PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR ITS AND USES THEREOF | |
| EP2997009A4 (en) | Process for the preparation of arformoterol or salt thereof | |
| PT3330271T (pt) | Composto de pirrolo[2,3-d]pirimidina ou sal do mesmo | |
| EP3476843A4 (en) | PYRIMIDINE COMPOUND, CHLORIDE SALT THEREOF AND THEIR PRODUCTION AND USE | |
| EP3257851A4 (en) | Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate |